flow trial semaglutide kidney outcomes 2024 nejm hazard ratio clinical (funded by Novo Nordisk): showed 24% reduction in the risk of disease-related events in people with type 2 diabetes and chronic kidney disease compared to placebo. Investigators Semaglutide could be 'practice changing'

Understanding GLP-1 medications GLP-1 (glucagon-like peptide-1) receptor agonists, like semaglutide (the active ingredient in Ozempic and Wegovy), act like the GLP-1 hormone thats naturally made in your body

We treat every client with the dignity and respect they deserve, taking time to listen to their story and explain their options in plain language.

Alongside protein, fibre intake often drops, and some people experience bloating, nausea or constipation, particularly in the early weeks

ACE2 was initially reported to be predominantly expressed in the respiratory system 53

Clinical trials evaluating semaglutide for weight management, including the pivotal STEP (Semaglutide Treatment Effect in People with obesity) programme published in the New England Journal of Medicine (2021), did not demonstrate a statistically significant increase in UTI incidence compared to placebo groups